NCT07057765 Predictive Value of CRP, Albumin, CAR, and mGPS in Treatment Outcomes of DLBCL
| NCT ID | NCT07057765 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ain Shams University |
| Condition | DLBCL - Diffuse Large B Cell Lymphoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-05-05 |
| Primary Completion | 2026-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 40 participants in total. It began in 2025-05-05 with a primary completion date of 2026-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This observational study evaluates the predictive value of systemic inflammatory markers-CRP, albumin, CRP-to-albumin ratio (CAR), and modified Glasgow Prognostic Score (mGPS)-in patients with diffuse large B-cell lymphoma (DLBCL) receiving R-CHOP chemotherapy. The study examines associations with treatment response, toxicity, and clinical characteristics.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years and ≤ 65 years * Pathologically confirmed, treatment-naïve diffuse large B-cell lymphoma (DLBCL) * Any stage of disease (nodal or extra-nodal), with or without B symptoms * Scheduled to receive standard systemic treatment (R-CHOP) * ECOG performance status 0-2 * Baseline normal: * Complete blood count (CBC) * Hepatitis viral markers * Liver and renal function tests * Urine analysis * Echocardiogram * Additional investigations to exclude current infection if clinically indicated Exclusion Criteria: * History of other concurrent or previous malignancies * Relapsed or refractory DLBCL * Uncontrolled comorbid conditions that may interfere with study participation, including: * Diabetes mellitus * Autoimmune diseases * Active infections * Chronic inflammatory diseases * Cardiac dysfunction * Liver cell failure * Pregnant females
Contact & Investigator
Mahmoud M Ellithy, MD
PRINCIPAL INVESTIGATOR
Faculty of Medicine, Ain Shams University
Frequently Asked Questions
Who can join the NCT07057765 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying DLBCL - Diffuse Large B Cell Lymphoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07057765 currently recruiting?
Yes, NCT07057765 is actively recruiting participants. Contact the research team at alaa.abdou@med.asu.edu.eg for enrollment information.
Where is the NCT07057765 trial being conducted?
This trial is being conducted at Cairo, Egypt.
Who is sponsoring the NCT07057765 clinical trial?
NCT07057765 is sponsored by Ain Shams University. The principal investigator is Mahmoud M Ellithy, MD at Faculty of Medicine, Ain Shams University. The trial plans to enroll 40 participants.